Targeting the inflammasome in rheumatic diseases

Article ID	Journal	Published Year	Pages	File Type
6155939	Translational Research	2016	13 Pages	PDF

Abstract

Activation of the inflammasome, a protein complex responsible for many cellular functions, including the activation of the proinflammatory cytokines interleukin (IL)-1Î² and IL-18, has been identified as a key participant in many rheumatic diseases including autoimmune, inflammatory, and autoinflammatory syndromes. This review will discuss the recent advances in understanding the role of this complex in various rheumatic diseases. Furthermore, it will focus on available therapies, which directly and indirectly target the inflammasome and its downstream cytokines to quiet inflammation and possibly dampen autoimmune processes.

Keywords

s-JIA Systemic onset juvenile idiopathic arthritis FMF RIG-I AIM2 NLR CAPS PBMCs IL-1RA TLR AOSD CPPD MSU HIDS ASC NOMID NSAID PAPA neonatal-onset multisystem inflammatory disease retinoic acid–inducible gene I NFκB ROS Rheumatoid arthritis IL-1 receptor antagonist Ankylosing spondylitis Fatty acids interleukin Adult-onset Still's disease Familial Mediterranean fever Traps Toll-like receptor nonsteroidal anti-inflammatory drug caspase-recruitment domain peripheral blood mononuclear cells Cryopyrin-associated periodic syndrome nuclear factor κB Systemic lupus erythematosus SLE Monosodium urate apoptosis-associated speck-like protein containing a caspase recruitment domain absent in melanoma 2 CARD Reactive oxygen species Nod-like receptor